Indonesia's white shrimp faces another "red light": FDA's concentrated refusal of entry raises export compliance risks.

It is worth noting that the 7 batches of rejected Indonesian shrimp products were all from the same export company. The FDA stated in its announcement that the products were found to contain prohibited antibiotics and other veterinary drug residues during random checks, triggering the U.S. import safety red line. Single enterprise "mass failure" is not an isolated incident At first glance, this incident seems to be a case of quality management failure by a single enterprise; however, from the regulatory pace and historical data, it reflects a continued, high-intensity systemic enforcement trend by the U.S. market on shrimp drug residue issues. FDA data shows that in the nearly nine years from 2016 to 2024, only 8 batches of Indonesian shrimp products were refused entry due to veterinary drug residue issues; however, in January 2026 alone, there were already 7 batches, almost matching the total quantity of previous years. This change indicates that the regulatory "threshold" is ...